undamentalytics Newsletter
Sign in

Cryoport, Inc. income statement

In fiscal 2025, Cryoport, Inc. reported revenue of $176m, up 12.4% on the year before, operating income of −$36.8m (a -20.9% margin) and net income of $78.3m, or $1.40 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132014Mar 20142015Mar 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue01134812203479223237169157176186
Cost of revenue11223569174212613393879399
Gross profit−1−1−001361017369710475708388
Research and development0000011249171618181718
Selling, general and administrative46556———315798120108110103110
Selling and marketing—————557————————
General and administrative—————6710————————
Operating income−6−7−6−5−6−9−8−9−18−30−18−32−101−122−37−40
Interest expense1101100013566422
Provision for credit losses——————————001———
Income before tax−6−8−6−20−7−13−8−10−18−33−274−35−84−104−32−31
Income tax000000000−0220022
Net income−6−8−6−20−7−13−8−10−18−33−276−37−100−11578−37
Diluted EPS−$1.84−$1.08−$0.68−$1.60−$0.81−$0.93−$0.34−$0.34−$0.55−$1.94−$6.18−$0.93−$2.21−$2.49$1.40−$0.75
Diluted shares (average)3m9m10m12m15m14m23m28m33m39m46m49m49m49m50m50m
EBITDA−5−7−6−5−5−8−7−8−15−202−9−73−91−9−14

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CTKB vs CYRXCYRX vs MRVICYRX vs GRALCYRX vs PACB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Cryoport, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cryoport, Inc.